NOXXON Receives Research Grant from the Federal Ministry of Education and Research

Berlin, Germany, (PresseBox) - NOXXON announced today that the company was awarded a research grant from Germany s Federal Ministry of Education and Research (BMBF). NOXXON will receive approximately one million Euro in research funding under the BioChancePlus initiative, a program that supports innovative research in biotechnology companies. The program is dedicated to further strengthen and broaden NOXXON s drug discovery platform to identify innovative medicines based on mirror-image oligonucleotides (Spiegelmers®). NOXXON s Chief Scientific Officer Dr. Sven Klussmann commented: "We are delighted that the government has decided to reward NOXXON s excellent research. The funding will be beneficial in supporting the development and growth of existing and new technologies."

Noxxon Pharma AG

Based on one of best protected technology platforms in the industry, NOXXON Pharma AG develops biostable aptamers, novel substances using mirror image nucleic acids. These so-called Spiegelmers® (the German word "Spiegel" means mirror) are highly specific for the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Press releases you might also be interested in

Weitere Informationen zum Thema "Forschung und Entwicklung":

Diagnose mit der Intelligenz des Bauchgefühls

Ein Sound-Er­ken­nungs­sys­tem ana­ly­siert tech­ni­sche Pro­b­le­me bei Ma­schi­nen auf der Grund­la­ge von Be­triebs­ge­räu­schen und löst Alarm aus.

Weiterlesen

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.